EuroPharma Today

For Novartis, 2012 Is Set To Be A Bumpy Ride

With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.

U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy

Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.

Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe

German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.

Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

The End of The Euro: What Might It Mean For Pharma?

Companies struggle on how even to begin assessing impact of a possible Euro break-up.

The End of The Euro: What Might It Mean For Pharma?

Companies struggle on how even to begin assessing impact of a possible Euro break-up.

French Pharma Industry Pays The Price For Country’s Financial Woes

 

In an effort to shore up its credit rating, the French government has turned the financial screw on pharmaceutical manufacturers.

Lacking Mediator EC Tightens Pharmacovigilance Proposals

The biggest changes in the European Commission's revised proposals on how pharmaceutical manufacturers can provide information to patients don't have to do with communications to patients at all - they address reporting safety concerns to regulators.

Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs

The Swedish government published on Sept. 22 a framework directive designed to revolutionize the pricing, reimbursement of and access to patent-protected pharmaceuticals.

Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma

Germany's pharmaceutical sector restructuring law (AMNOG) is living up to the government's expectations by putting the brakes on the country's drug expenditure.